Cellular mechanism of oral absorption of solidified polymer micelles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 8, 2015, Pages 1993-2002

  Abramov, Eva ^a   Cassiola, Flavia ^b   Schwob, Ouri ^a   Karsh Bluman, Adi ^a   Shapero, Mara ^a   Ellis, James ^c   Luyindula, Dema ^b   Adini, Irit ^b   D'Amato, Robert J ^b   Benny, Ofra ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Caco 2; mPEG PLA; Nanomedicine; Oral delivery; Polymer micelles

Indexed keywords

DRUG PRODUCTS; ENCAPSULATION; LACTIC ACID; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; MOTION PICTURE EXPERTS GROUP STANDARDS; POLYETHYLENE GLYCOLS; POLYETHYLENES; POLYMERS;

CACO-2; ENDOCYTOSIS PATHWAY; GASTROINTESTINAL TRACT; INTESTINAL ABSORPTION; LOW DENSITY LIPOPROTEIN RECEPTORS; MPEG-PLA; ORAL DELIVERY; POLYMER MICELLES;

MICELLES;

CLATHRIN; COUMARIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; POLYLACTIC ACID; POLYMER; UNCLASSIFIED DRUG; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; MICELLE; MONOMETHOXYPOLYETHYLENE GLYCOL;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG TRANSPORT; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; INTESTINE ABSORPTION; MICELLE; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CACO 2 CELL LINE; CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; SMALL INTESTINE;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LACTIC ACID; MICE, INBRED C57BL; MICELLES; POLYETHYLENE GLYCOLS; POLYMERS;

EID: 84950999373     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.07.008     Document Type: Article

References (54)

1. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000, 44(1):235-249.
2. Qiu Y., Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001, 53(3):321-339.
3. Chourasia M.K., Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003, 6(1):33-66.
4. Chen H., Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev 1998, 34(2-3):339-350.
5. McDonald T.O., Giardiello M., Martin P., Siccardi M., Liptrott N.J., Smith D., et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthcare Mater 2014, 3(3):400-411.
6. Harde H., Das M., Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011, 8(11):1407-1424.
7. Sun J., Wang F., Sui Y., She Z., Zhai W., Wang C., et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q(1)(0) as naked nanocrystals. Int J Nanomedicine 2012, 7:5733-5744.
8. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996, 13(12):1838-1845.
9. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116(1):1-27.
10. Yun Y., Cho Y.W., Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 2013, 65(6):822-832.
11. Pinto-Alphandary H., Aboubakar M., Jaillard D., Couvreur P., Vauthier C. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res 2003, 20(7):1071-1084.
12. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001, 47:113-131.
13. Kakizawa Y., Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002, 54:203-222.
14. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
15. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 2008, 26(7):799-807.
16. Benny O., Nakai K., Yoshimura T., Bazinet L., Akula J.D., Nakao S., et al. Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PLoS One 2010, 5(9):e12515.
17. Takeru Y., Ofra B., Lauren B., Robert D.A. Suppression of autoimmune retinal inflammation by an antiangiogenic drug. PLoS One 2013, 8(6):e66219.
18. Hirst J., Robinson M.S. Clathrin and adaptors. Biochim Biophys Acta 1998, 1404(1-2):173-193.
19. Pelkmans L., Helenius A. Endocytosis via caveolae. Traffic 2002, 3(5):311-320.
20. Damm E.M., Pelkmans L., Kartenbeck J., Mezzacasa A., Kurzchalia T., Helenius A. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J Cell Biol 2005, 168(3):477-488.
21. Castro M.J.L., Ritacco H., Kovensky J., Fernandez-Cirelli A. A simplified method for the determination of critical micelle concentration. J Chem Educ 2001, 78:347-348.
22. Gao J., Hugger E.D., Beck-Westermeyer M.S., Borchardt R.T. Estimating intestinal mucosal permeation of compounds using Caco-2 cell monolayers. Curr Protoc Pharmacol 2001, 8:1-23.
23. Phonphok Y., Rosenthal K.S. Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines. FEBS Lett 1991, 281(1-2):188-190.
24. Wang L.H., Rothberg K.G., Anderson R.G. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993, 123(5):1107-1117.
25. Van Hamme E., Dewerchin H.L., Cornelissen E., Verhasselt B., Nauwynck H.J. Clathrin- and caveolae-independent entry of feline infectious peritonitis virus in monocytes depends on dynamin. J Gen Virol 2008, 89(Pt 9):2147-2156.
26. Schnitzer J.E., Oh P., Pinney E., Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol 1994, 127(5):1217-1232.
27. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci 2003, 116(Pt 23):4707-4714.
28. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001, 299(2):483-493.
29. Zastre J., Jackson J.K., Wong W., Burt H.M. Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity. J Pharm Sci 2007, 96(4):864-875.
30. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782.
31. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91(10):1775-1781.
32. Plummer R., Wilson R.H., Calvert H., Boddy A.V., Griffin M., Sludden J., et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011, 104(4):593-598.
33. Gaucher G., Satturwar P., Jones M.C., Furtos A., Leroux J.C. Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 2010, 76(2):147-158.
34. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8(2):147-166.
35. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012, 164(2):138-144.
36. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63(3):136-151.
37. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6(12):815-823.
38. Tian Y., Mao S. Amphiphilic polymeric micelles as the nanocarrier for peroral delivery of poorly soluble anticancer drugs. Expert Opin Drug Deliv 2012, 9(6):687-700.
39. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 1991, 8(4):305-330.
40. Abel-Rahman A.A., Abdel-Bary H.M., Pedersen E.B., Nielsen C. Synthesis of 4-methylthio analogues of FLT and AZT and their evaluation against HIV. Arch Pharm 1995, 328(1):67-70.
41. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
42. Mathot F., des Rieux A., Arien A., Schneider Y.J., Brewster M., Preat V. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J Control Release 2007, 124(3):134-143.
43. Zastre J.A., Jackson J.K., Wong W., Burt H.M. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity. Mol Pharm 2008, 5(4):643-653.
44. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013, 65(13-14):1748-1762.
45. Gres M.C., Julian B., Bourrie M., Meunier V., Roques C., Berger M., et al. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 1998, 15(5):726-733.
46. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 1997, 14(6):763-766.
47. Sato K., Nagai J., Mitsui N., Ryoko Y., Takano M. Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sci 2009, 85(23-26):800-807.
48. Schmid S.L., Carter L.L. ATP is required for receptor-mediated endocytosis in intact cells. J Cell Biol 1990, 111(6 Pt 1):2307-2318.
49. Torgersen M.L., Skretting G., van Deurs B., Sandvig K. Internalization of cholera toxin by different endocytic mechanisms. J Cell Sci 2001, 114(Pt 20):3737-3747.
50. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006, 58(1):32-45.
51. Lamaze C., Schmid S.L. The emergence of clathrin-independent pinocytic pathways. Curr Opin Cell Biol 1995, 7(4):573-580.
52. Ivanov A.I. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?. Methods Mol Biol 2008, 440:15-33.
53. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011, 12(8):517-533.
54. Kim H.R., Gil S., Andrieux K., Nicolas V., Appel M., Chacun H., et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007, 64(3):356-364.